Company Overview of Excelimmune, Inc.
Excelimmune, Inc. develops antibody combination therapeutics for the treatment of monotherapy-resistant infectious and oncological diseases. The company develops Staphguard ACT, a novel treatment for methicillinresistant staphylococcus aureus infection. It offers technology treatments for combination therapies, infectious diseases, oncology, and autoimmunity. Excelimmune, Inc. was incorporated in 2006 and is based in Lexington, Massachusetts.
1776 Massachusetts Avenue
Lexington, MA 02420
Founded in 2006
Key Executives for Excelimmune, Inc.
Excelimmune, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Bloomberg L.P.||United States|
Sponsored Financial Commentaries
To contact Excelimmune, Inc., please visit www.excelimmune.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.